Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
March 28, 2024 08:30 ET
|
Third Harmonic Bio
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
March 26, 2024 08:05 ET
|
Third Harmonic Bio
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO,...
Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference
February 26, 2024 16:00 ET
|
Third Harmonic Bio
SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update
January 04, 2024 08:00 ET
|
Third Harmonic Bio
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing completion;...
Third Harmonic Bio Announces Third Quarter 2023 Financial Results
November 09, 2023 08:30 ET
|
Third Harmonic Bio
On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24 Strong financial position with cash and cash equivalents totaling $273.9...
Third Harmonic Bio Announces Leadership Changes
October 31, 2023 08:30 ET
|
Third Harmonic Bio
SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference
August 31, 2023 08:30 ET
|
Third Harmonic Bio
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...
Third Harmonic Bio Announces Second Quarter 2023 Financial Results
August 10, 2023 08:10 ET
|
Third Harmonic Bio
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic,...
Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335
July 25, 2023 08:30 ET
|
Third Harmonic Bio
THB335 retains selectivity and potency of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution and physicochemical profile THB001 demonstrated evidence of...
Third Harmonic Bio Announces First Quarter 2023 Financial Results
May 11, 2023 17:00 ET
|
Third Harmonic Bio
SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today...